NORTH KINGSTOWN, R.I., June 15 /PRNewswire/ — At the
forefront of the ongoing effort to enhance addiction treatment
outcomes, one leading Rhode Island Company has announced the
next-generation clinical laboratory diagnostics tool designed to
assist clinicians.
Dominion Diagnostics (Dominion), a privately-held clinical urine
drug testing laboratory, today announced the release of its new
Comprehensive Analysis of Reported Drugs (CARD)™ results, a
unique clinical laboratory reporting service that provides
clinicians with accurate testing results and analytical feedback to
augment the assessment and monitoring of an individual’s drug use
upon admission and throughout the course of addiction
treatment.
Dominion developed its CARD™ reporting service to create a
highly personalized clinical report by correlating an individual’s
prescribed medication use and self-reported drug misuse with its
state-of-the-art diagnostic testing.
CARD™ utilizes laboratory results from
validated quantitative urine drug testing profiles for commonly
abused illicit and prescription drugs and/or their metabolites, as
well as biological markers and commercial adulterant screening
(i.e., creatinine, specific gravity, pH, and oxidants) to ensure
specimen validity. CARD™ employs a supplied
list of prescribed treatment-related medications and self-reported
non-prescribed drug misuse, along with documented pharmaceutical
and pharmacokinetic references backed by Dominion’s expert Clinical
Services team of pharmacists.
Dominion’s CARD™ results provide data to support and
measure a treatment program’s ability to reduce morbidity in
substance abuse, improve retention in treatment, and promote the
use of evi
‘/>”/>
SOURCE
